A Phase II Study of Perioperative Capecitabine plus Oxaliplatin Therapy for Clinical SS/SE N1-3 M0 Gastric Cancer (OGSG 1601).
Tetsuji TerazawaJin MatsuyamaMasahiro GotoRyohei KawabataShunji EndoMotohiro ImanoShoichiro FujitaYusuke AkamaruHirokazu TaniguchiMitsutoshi TatsumiSang-Woong LeeYoshitaka KurisuHisato KawakamiYukinori KurokawaToshio ShimokawaDaisuke SakaiTakeshi KatoKazumasa FujitaniTaroh SatohPublished in: The oncologist (2019)
Perioperative CapeOx showed good feasibility and favorable efficacy with sufficient pathological response, although statistical significance at .058 did not reach the commonly accepted cutoff of .05. The data obtained using this novel approach warrant further investigations.